<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090410</url>
  </required_header>
  <id_info>
    <org_study_id>CRB20_026</org_study_id>
    <nct_id>NCT05090410</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate</brief_title>
  <acronym>TRANSFORM</acronym>
  <official_title>Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate: Comparative Study With Filgotinib and Tocilizumab Examined by Clinical Index as Well as Musculoskeletal Ultrasound Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atsushi Kawakami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nagasaki University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The administration of Janus kinase (JAK) inhibitors as well as biological disease-modifying&#xD;
      anti-rheumatic drugs has dramatically improved even the clinical outcomes in rheumatoid&#xD;
      arthritis (RA) patients with inadequate response to methotrexate (MTX). The dysregulation of&#xD;
      JAK-signal transducer and activator of transcription (STAT) pathways via overproduction of&#xD;
      cytokines, such as interleukin-6 (IL-6) is involved in the pathogenesis of RA. Filgotinib is&#xD;
      a selective JAK1 inhibitor to be approved for use in RA. Filgotinib is effective in&#xD;
      suppressing disease activity and preventing the progression of joint destruction due to&#xD;
      inhibition of the JAK-STAT pathway. IL-6 inhibitors such as tocilizumab also inhibit the&#xD;
      JAK-STAT pathways due to inhibition of IL-6 signaling. We will evaluate whether the&#xD;
      effectiveness and safety of filgotinib monotherapy is non-inferior to those of tocilizumab&#xD;
      monotherapy in RA patients with inadequate response to MTX.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients who achieve an American College of Rheumatology (ACR) 50 response</measure>
    <time_frame>at week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients who achieve an ACR20 response</measure>
    <time_frame>at weeks 2, 4, 8, 12, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients who achieve an ACR50 response</measure>
    <time_frame>at weeks 2, 4, 8, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients who achieve an ACR70 response</measure>
    <time_frame>at weeks 2, 4, 8, 12, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the clinical disease activity index (CDAI) value</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active of RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the simplified disease activity index (SDAI) value</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the Disease Activity Score (DAS)28-ESR value</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the DAS28-CRP value</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the serum levels of biomarkers</measure>
    <time_frame>from baseline to weeks 2, 4, 12, 24, 36, and 52</time_frame>
    <description>We analyze the serum levels of multiple biomarkers such as cytokines and chemokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the total power Doppler (PD) score</measure>
    <time_frame>from baseline to weeks 4, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the total grayscale (GS) score</measure>
    <time_frame>from baseline to weeks 4, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the combined PD score</measure>
    <time_frame>from baseline to weeks 4, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in van der Heijde-modified total Sharp score (vdH-mTSS)</measure>
    <time_frame>from baseline to weeks 24 and 52</time_frame>
    <description>Higher scores mean a more joint destruction and deformity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the Health Assessment Questionnaire-Disability Index (HAQ-DI) data</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the EuroQol 5 Dimensions 5-Level (EQ-5D-5L) data</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a worse QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the Functional Assessment of Chronic Illness-Fatigue (FACIT-F) data</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a worse fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the morning stiffness duration</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the morning stiffness activity</measure>
    <time_frame>from baseline to weeks 2, 4, 8, 12, 24, 36, and 52</time_frame>
    <description>We analyze the visual analog scale of morning stiffness activity. Higher scores mean a more active RA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>JAK Inhibitor</condition>
  <condition>IL-6 Inhibitor</condition>
  <condition>Musculoskeletal Ultrasound</condition>
  <condition>Biomarker</condition>
  <arm_group>
    <arm_group_label>Filgotinib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The administration of filgotinib 200mg/day switched from MTX ± other csDMARDs throughout the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The administration of subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgotinib 200mg/day</intervention_name>
    <description>Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.</description>
    <arm_group_label>Filgotinib monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous tocilizumab 162mg/biweekly</intervention_name>
    <description>Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.</description>
    <arm_group_label>Tocilizumab monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must meet all of the following requirements to be considered for entry into&#xD;
             the study:&#xD;
&#xD;
               1. ≥20 years old&#xD;
&#xD;
               2. with the diagnosis of RA based on the ACR/EULAR 2010 RA Classification Criteria&#xD;
&#xD;
               3. with at least moderate disease activity defined as a DAS28-ESR ≥3.2 at the&#xD;
                  eligibility evaluation&#xD;
&#xD;
               4. treated with MTX for ≥8 weeks prior to the providing consent, including 4 weeks&#xD;
                  or more at the same doses of 8 to 16 mg per week (stable doses of &lt;8 mg per week&#xD;
                  are allowed only in the presence of intolerance to higher doses)&#xD;
&#xD;
               5. ability and willingness to provide written informed consent and comply with the&#xD;
                  requirements of the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The exclusion criteria are as follows:&#xD;
&#xD;
               1. concurrent use of a corticosteroid equivalent to &gt;5 mg/day of prednisolone&#xD;
&#xD;
               2. applicable an item for the contraindication of filgotinib or tocilizumab&#xD;
&#xD;
               3. a previous use of a JAK inhibitor or IL-6 inhibitor&#xD;
&#xD;
               4. treatment with a corticosteroid and csDMARD and change of dose within 4 weeks&#xD;
                  prior to the providing consent&#xD;
&#xD;
               5. treatment with a biologic DMARD or a biosimilar DMARD (ie, infliximab, biosimilar&#xD;
                  of infliximab, adalimumab, biosimilar of adalimumab, golimumab, certolizumab&#xD;
                  pegol or abatacept) within 8 weeks prior to the providing consent&#xD;
&#xD;
               6. treatment with a TNF inhibitor (ie, etanercept or biosimilar of etanercept)&#xD;
                  within 4 weeks prior to the providing consent&#xD;
&#xD;
               7. use of a prohibited drug or therapy, other than the agents noted above, within 4&#xD;
                  weeks prior to the providing consent&#xD;
&#xD;
               8. a complication causing musculoskeletal disorders other than RA (ie, ankylosing&#xD;
                  spondyloarthritis, reactive arthritis, psoriatic arthritis, crystal-induced&#xD;
                  arthritis, systemic lupus erythematosus, systemic scleroderma, inflammatory&#xD;
                  myopathy, or mixed connective tissue disease)&#xD;
&#xD;
               9. current pregnancy, breastfeeding, or noncompliant with a medically approved&#xD;
                  contraceptive regimen during and 12 months after the study period&#xD;
&#xD;
              10. inappropriateness for inclusion in this study as determined by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atsushi Kawakami, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nagasaki University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atsushi Kawakami, MD, PhD</last_name>
    <phone>+81-95-819-7260</phone>
    <email>atsushik@nagasaki-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Toshimasa Shimizu, MD, PhD</last_name>
    <phone>+81-95-819-8527</phone>
    <email>t.shimizu@nagasaki-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsushi Kawakami, MD, PhD</last_name>
      <phone>+81-95-819-7260</phone>
      <email>atsushik@nagasaki-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Toshimasa Shimizu, MD, PhD</last_name>
      <phone>+81-95-819-8527</phone>
      <email>t.shimizu@nagasaki-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Atsushi Kawakami, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nagasaki University</investigator_affiliation>
    <investigator_full_name>Atsushi Kawakami</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

